<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Health Net, Inc. Provides Coverage for Biodesix’ VeriStrat Test 

    July 13, 2015

    HealthNet now covers Biodesix' VeriStrat test

    Biodesix’ GeneStrat Blood-Based Mutation Test Now Includes EML4-ALK Fusions

    January 7, 2016

    GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.

    Biodesix Raises Follow-On Series E Financing

    June 23, 2015

    Biodesix raises follow-on series E financing

    Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures

    July 29, 2015

    Biodesix recently added Biognosys' Proteomics to their capabiltites.

    Biodesix Named To Inc. 500|5000 Fastest-Growing Private Companies List

    August 13, 2015

    Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list

    VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study Results Presented at 16th World Conference On Lung Cancer

    September 7, 2015

    VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer

    Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)

    November 6, 2015

    Biodesix data on proteomic and genomic blood-based assays presented at EORTC

    Aetna Provides Coverage for Biodesix’ VeriStrat Test

    June 8, 2015

    Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.

    Biodesix to Present at Leerink Partners 5th Annual Global Healthcare Conference

    February 11, 2016

    Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference

    Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ blood test is independent of PD-L1 expression

    November 3, 2015

    Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.
    3 4 5 6 7 8 9 10 11